Grandaxin (Tofisopam)

Grandaxin (tofisopam) is indicated for the short‑term treatment of anxiety disorders in adults.

• Management of generalized anxiety disorder (GAD).
• Adjunctive therapy for anxiety associated with depressive disorders.
• Relief of situational anxiety such as performance anxiety.
• Treatment of anxiety symptoms in patients who experience sedation with other benzodiazepines.
• Short‑term use to reduce acute anxiety episodes.
• Supportive treatment for anxiety in patients undergoing medical procedures where rapid anxiolysis is desired.
• Use as an alternative when conventional benzodiazepines cause excessive drowsiness or cognitive impairment.

The safety profile of Grandaxin reflects its anxiolytic activity with a relatively low incidence of sedation compared with many benzodiazepines.

Common

• Mild drowsiness or fatigue, typically occurring during the first few days of therapy and often diminishing with continued use.
• Lightheadedness or dizziness, which may be more noticeable when standing up quickly.
• Gastrointestinal discomfort such as nausea, abdominal cramping, or mild diarrhea.
• Transient headache that is usually mild to moderate in intensity.

Serious

• Allergic reactions including rash, itching, swelling of the face, lips, tongue, or throat, which may require immediate medical attention.
• Mood changes such as new or worsening depression, anxiety, or thoughts of self‑harm, warranting prompt evaluation.

When prescribing Grandaxin, clinicians should evaluate patient history and monitor for conditions that could affect safety or efficacy.

• Assess for a history of severe hepatic or renal impairment before initiating therapy.
• Use caution in patients with a known hypersensitivity to thienodiazepines or related compounds.
• Evaluate the risk of dependence or abuse, especially in individuals with a substance‑use disorder.
• Monitor for signs of depression or suicidal ideation during treatment.
• Avoid abrupt discontinuation; taper the dose gradually to reduce the potential for withdrawal symptoms.
• Consider dose adjustment in elderly patients due to increased sensitivity to central nervous system effects.

Grandaxin may interact with other medicines that influence the central nervous system or hepatic metabolism, potentially altering its effectiveness or safety.

Avoid

• Concomitant use with other potent CNS depressants such as barbiturates, opioids, or alcohol, which can increase sedation and respiratory depression.
• Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise tofisopam plasma concentrations.

Use with caution

• Combination with other anxiolytics or antidepressants, requiring close monitoring for additive effects.
• Use alongside medications metabolized by CYP3A4 (e.g., certain antiepileptics) as dose adjustments may be needed.
• Concurrent use with herbal supplements like St. John’s wort, which can induce CYP enzymes and reduce drug levels.